CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript – Image for illustrative purposes only (Image credits: Pexels)
Brisbane, California — Transplant patients and investors alike stand to benefit from CareDx Inc.'s first-quarter 2026 performance, which delivered profitability and accelerated growth in precision diagnostics. The company reported total revenue of $118 million on April 28, a 39 percent increase from the prior year, driven by robust demand for testing services that monitor organ rejection.[1][2] Executives highlighted strategic shifts, including a lab products divestiture and an oncology acquisition, that refocus resources on high-margin areas with repeat testing needs. Cash collections hit a record, bolstering the balance sheet for transplant centers and shareholders navigating reimbursement challenges.
Testing Services Fuel Revenue Surge
Testing services revenue rose 48 percent to $91 million, accounting for the bulk of the quarter's gains. Volume increased 17 percent to approximately 54,900 tests, reflecting stronger adoption of surveillance and for-cause monitoring in kidney, heart, and lung transplants.[2] Average revenue per test reached about $1,660, boosted by $14 million in prior-period collections that added $260 per test.
Patient and digital solutions grew 33 percent to $16 million, supported by pharmacy adoption and tools like Epic integrations now live at nine centers with 16 more in progress. Lab products dipped 4 percent to $10 million as CareDx prioritized core diagnostics. Non-GAAP gross margins improved to 73 percent, while operating expenses held at 59 percent of revenue despite a $2 million bonus accrual for outperformance.[1]
| Key Q1 2026 Metrics | Q1 2026 | Q1 2025 | YoY Change |
|---|---|---|---|
| Total Revenue | $118 million | $85 million | +39% |
| Testing Services Revenue | $91 million | N/A | +48% |
| Testing Volume | 54,900 | N/A | +17% |
| GAAP Net Income | $3 million | ($10 million) | Profitable |
| Adjusted EBITDA | $19 million | $5 million | +300% |
Portfolio Actions Sharpen Strategic Focus
CareDx signed a deal on April 15 to sell its Lab Products business to Eurobio Scientific for $170 million in upfront cash, netting about $160 million after expenses. The transaction, expected to close by the third quarter, eliminates a low-margin segment that generated $10 million in Q1 revenue and less than $1 million in adjusted EBITDA.[2] This move simplifies operations and frees capital for precision medicine investments.
Simultaneously, the company announced the acquisition of Navaris, expanding into oncology monitoring for HPV-driven cancers like head, neck, and anal. Navaris has performed over 130,000 tests with 2,000 active physicians and holds ADLT designation at $1,800 per test, covered for 100 million lives. Its tumor-naive blood test offers 98 percent negative predictive value and detects recurrence four months early. "Navaris has a differentiated technology, and that technology makes it a preferential tool in the monitoring and diagnosis of these patients," noted CEO John W. Hanna.[2] The deal targets a $4.5 billion market in solid tumors, with no contribution baked into 2026 guidance.
Pipeline Momentum and Operational Wins
Clinical progress included presentation of AlloHeme trial data at the TANDEM conference and advancements in AlloSure Liver and HistoMap Kidney programs. CareDx launched VANTx, an AI platform for transplant data insights, and showcased over 50 abstracts from 95 centers at the ISHLT meeting.[1] These efforts underscore leadership in molecular surveillance, where kidney for-cause testing now represents half of volume.
Operational execution shone through record $121 million cash collections, up 52 percent, generating $4 million in operating cash flow. The company ended the quarter with $198 million in cash and no debt. A new $100 million share repurchase program over 24 months signals confidence in valuation. Epic integrations aim for 50 percent of testing volume by year-end, easing clinician workflows.[2]
Raised Outlook Reflects Sustained Growth
CareDx lifted its full-year 2026 revenue guidance to $447 million to $465 million, implying 20 percent growth at the midpoint, from a prior $420 million to $444 million range. Adjusted EBITDA now targets $43 million to $57 million. Testing volume guidance sits at 224,000 to 229,000, with revenue per test rising 10 percent to $1,460 by December amid automation and collections improvements.[1]
Assumptions factor a $7.5 million LCD pricing headwind on revenue but not volume, plus Lab Products until divestiture. Quarterly gross margins should range 68 to 71 percent, with operating expenses at $68 million to $70 million. "Our team delivered another quarter of record growth, driven by continued momentum in our Precision Medicine Testing Services," Hanna stated.[1] Analysts probed Navaris synergies and transplant trends in Q&A, with management emphasizing volume-driven oncology growth and no immediate need for sales expansion.
For transplant recipients relying on timely rejection detection and cancer patients seeking early recurrence signals, CareDx's pivot promises more accessible, data-backed care. Shareholders gain from enhanced margins and buybacks, though LCD risks loom mid-year. The coming quarters will test execution in these expanded markets.
